NCT01024062View on ClinicalTrials.gov

Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Non-Small Cell Lung Cancer (NSCLC)

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 31, 2002

Primary Completion Date

March 31, 2005

Study Completion Date

March 31, 2005

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

Paclitaxel

Solution, IV, 100 mg/m², weekly for 6 of 7 weeks, until disease progression or unacceptable toxicity became apparent

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY